Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril/Valsartan in HFpEF with Recent Decompensation
NCT03988634Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of sacubitril + valsartan in heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by Novartis. Primary endpoint: Time-averaged Proportional Change in NT-proBNP at Week 8. Started Jun 2019; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT03988634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03988634.